MET and MST1R as prognostic factors for classical Hodgkin's lymphoma

Modern Pathology

Volumn 26, Issue 9, 2013, Pages 1172-1182

  Wha Koh, Young ^a   Park, Chansik ^a   Hyun Yoon, Dok ^a   Suh, Cheolwon ^a   Huh, Jooryung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Hodgkins lymphoma; MET; mRNA; MST1R; prognosis

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; LACTATE DEHYDROGENASE; MESSENGER RNA; MST1R PROTEIN; PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILD; CLASSICAL HODGKIN LYMPHOMA; COMBINATION CHEMOTHERAPY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; BIOPSY; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84883886078     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.64     Document Type: Article

References (65)

1. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30\+ Hodgkin cells. Cancer Res 2000;60:549-552. (Pubitemid 30094549)
2. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006;25:2679-2684.
3. Portis T, Dyck P, Longnecker R. Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003;102:4166-4178. (Pubitemid 37487004)
4. Vockerodt M, Morgan SL, Kuo M, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol 2008; 216:83-92.
5. Koh YW, Yoon DH, Suh C, et al. Impact of the Epstein-Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea. Ann Hematol 2012;91:1403-1412.
6. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2012;88:292-305.
7. Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist 2012;17:871-880.
8. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-885.
9. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J 2009;15:161-163.
10. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
11. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752. (Pubitemid 47372616)
12. Diepstra A, van Imhoff GW, Schaapveld M, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009;27: 3815-3821.
13. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-325. (Pubitemid 36791889)
14. Benvenuti S, Comoglio PM. The METreceptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213:316-325. (Pubitemid 47509708)
15. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-516. (Pubitemid 351767118)
16. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902. (Pubitemid 29202761)
17. Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007; 248:219-228. (Pubitemid 46330555)
18. Edakuni G, Sasatomi E, Satoh T, et al. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 2001;51:172-178. (Pubitemid 32337066)
19. Aune G, Lian AM, Tingulstad S, et al. Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol 2011;121:402-406.
20. Tanimoto S, Fukumori T, El-Moula G, et al. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest 2008;55:106-111. (Pubitemid 351643600)
21. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47: 1025-1037.
22. Ramirez R, Hsu D, Patel A, et al. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2000;53:635-644.
23. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65: 1479-1488. (Pubitemid 40270177)
24. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-2666.
25. Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004;90:1555-1562. (Pubitemid 38648238)
26. Chen YQ, Zhou YQ, Angeloni D, et al. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 2000;261:229-238.
27. Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 2003;24:1291-1300. (Pubitemid 37038819)
28. Bardella C, Costa B, Maggiora P, et al. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 2004;64: 5154-5161. (Pubitemid 39006533)
29. Wang MH, Kurtz AL, Chen Y. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 2000;21:1507-1512. (Pubitemid 30603978)
30. Weimar IS, de Jong D, Muller EJ, et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 1997;89:990-1000. (Pubitemid 27121293)
31. Renne C, Willenbrock K, Martin-Subero JI, et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 2007;21:780-787. (Pubitemid 46444563)
32. Xu C, Plattel W, van den Berg A, et al. Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. Haematologica 2012;97:572-578.
33. Chen Q, Seol DW, Carr B, et al. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 1997;26:59-66. (Pubitemid 27280307)
34. Cheng HL, Liu HS, Lin YJ, et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005;92:1906-1914.
35. Huh J, Cho K, Heo DS, et al. Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. Am J Hematol 1999;60:205-214. (Pubitemid 29108771)
36. Nakopoulou L, Gakiopoulou H, Keramopoulos A, et al. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000;36:313-325. (Pubitemid 30198913)
37. Uddin S, Hussain AR, Ahmed M, et al. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest 2010;90: 1346-1356.
38. Hui MK, Lai KK, Chan KW, et al. Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma. Med Oncol 2011;29:1699-1706.
39. Catenacci DV, Cervantes G, Yala S, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 2011;12:9-46.
40. Bishop EA, Lengyel ER, Yamada SD, et al. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol 2011;121:218-223.
41. Zhou D, Pan G, Zheng C, et al. Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. BMC Cancer 2008;8:353.
42. Lin Y, Xie WF, Chen YX, et al. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int 2005;25:796-807. (Pubitemid 41038661)
43. Xue F, Takahara T, Yata Y, et al. Attenuated acute liver injury in mice by naked hepatocyte growth factor gene transfer into skeletal muscle with electroporation. Gut 2002;50:558-562. (Pubitemid 34638878)
44. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-230. (Pubitemid 29068532)
45. Poppema S, Potters M, Visser L, et al. Immune escape mechanisms in Hodgkin's disease. Ann Oncol 1998;9(Suppl 5):S21-S24. (Pubitemid 29049113)
46. Chou YC, Lin SJ, Lu J, et al. Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation. Blood 2011;118: 1340-1349.
47. Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al. Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 2008;14:1759-1766. (Pubitemid 351469461)
48. Dinand V, Malik A, Unni R, et al. Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer 2008;50:280-283.
49. Tiemann M, Claviez A, Luders H, et al. Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase. Mod Pathol 2005;18:1440-1447. (Pubitemid 41509398)
50. Druillennec S, Dorard C, Eychene A. Alternative splicing in oncogenic kinases: from physiological functions to cancer. J Nucleic Acids 2012;2012:639062.
51. Lee JM, Yoo JK, Yoo H, et al. The novel miRNA hc-smR-S2-5 decrease the proliferation and migration of human lung cancer cells by targeting c-Met. Mol Cancer Res 2012;11:43-53.
52. Migliore C, Petrelli A, Ghiso E, et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res 2008;68:10128-10136.
53. Jang KW, Lee JE, Kim SY, et al. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation. J Thorac Oncol 2011;6:679-687.
54. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-154.
55. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-1555. (Pubitemid 30175676)
56. Peace BE, Hughes MJ, Degen SJ, et al. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene 2001;20: 6142-6151. (Pubitemid 32964426)
57. Senchenko VN, Liu J, Loginov W, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 2004;23:5719-5728. (Pubitemid 39093017)
58. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925. (Pubitemid 37493640)
59. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009;19:542-551.
60. Danilkovitch A, Donley S, Skeel A, et al. Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cells. Mol Cell Biol 2000;20:2218-2227. (Pubitemid 30123837)
61. Follenzi A, Bakovic S, Gual P, et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000;19:3041-3049. (Pubitemid 30438460)
62. Lee WY, Chen HH, Chow NH, et al. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005;11:2222-2228. (Pubitemid 40490180)
63. Lee CT, Chow NH, Su PF, et al. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum 2008;51:1268-1274.
64. Teofili L, Di Febo AL, Pierconti F, et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 2001;97: 1063-1069. (Pubitemid 32154294)
65. Rathore B, Kadin ME. Hodgkin's lymphoma therapy: past, present, and future. Expert Opin Pharmacother 2010;11:2891-2906.